The next-generation antibody market is expected to reach US$ 12,050.13 million by 2028 from US$ 5,468.41 million in 2021; it is estimated to grow at a CAGR of 11.9% from 2021 to 2028.
Next-generation antibodies are designed to be more specific and often more potent than traditional monoclonal antibodies. Next-generation antibody strategies are required to engineer a useful therapeutic combining antibody, payload, linker, and conjugation method while ensuring stability, targeted delivery, and limited off-target effects.
The report offers insights and in-depth analysis of the next-generation antibody market, emphasizing various parameters such as market trends, technological advancements, market dynamics, and competitive landscape analysis of leading market players worldwide. It also includes the impact of the COVID-19 pandemic on the market across all the regions. The pandemic has disrupted the socioeconomic conditions of various countries across the world. Presently, the US is the world's worst-affected country due to the COVID-19 outbreak with the highest number of confirmed cases and deaths across the world, as per the recent WHO statistics. The high number of COVID-19 positive cases has negatively impacted the global economies. There has been a decline in overall business activities and the growth of various industries operating worldwide.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Next-Generation Antibody Market: Strategic Insights
Market Size Value in US$ 5,468.41 million in 2021 Market Size Value by US$ 12,050.13 million by 2028 Growth rate CAGR of 11.9% from 2021 to 2028 Forecast Period 2021-2028 Base Year 2021
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Next-Generation Antibody Market: Strategic Insights
| Market Size Value in | US$ 5,468.41 million in 2021 |
| Market Size Value by | US$ 12,050.13 million by 2028 |
| Growth rate | CAGR of 11.9% from 2021 to 2028 |
| Forecast Period | 2021-2028 |
| Base Year | 2021 |
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
The COVID-19 outbreak has put an immense burden on healthcare infrastructure in the US, Canada, and Mexico. In addition, most pharmaceutical and biotechnological companies and research institutes are engaged in developing COVID-19 vaccines and drugs. Both set pharmaceutical companies and small startups have come forward to advance treatments and vaccines that target the infection created by the novel coronavirus. As a result, vaccine-related research activities in pharmaceutical and biotechnology companies, research centers, and educational research institutes are acknowledged essential and have been primarily unaffected in operations and output. However, due to the rise in research activities, both the accessibility of funding for analysis and the need for antibodies, including next-generation antibodies, are anticipated to grow. In addition, at the lead of the COVID-19 outbreak, many researchers worldwide are involved in the viral examination of SARS-CoV-2, the virus that develops COVID-19. For both vaccines and therapeutics, the antibodies generated are examined for their functional efficiency to counterbalance the target virus. Therefore, the COVID-19 pandemic is expected to positively impact the next-generation antibody market in the coming years.
Based on region, the next-generation antibody market is segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South and Central America.
Market Insights
Growing Demand for Next-Generation Antibody Therapeutics to Drive Next-Generation Antibody Market
Rising developments in biotechnology have led to an increasing acceptance for next-generation antibodies therapeutics, which is driving its use in autoimmune, inflammatory, and chronic diseases treatment. Next-generation antibody treatments have resulted from the application of sophisticated technologies in antibody therapeutics, such as antibody–drug conjugates (ADCs), glycoengineered antibodies, and specific antibodies (BsAbs). Therefore, applications of next-generation antibodies are being widely studied to treat various chronic diseases such as cancer, HIV, infectious diseases etc. The rising demand for these antibodies have resulted in the rapid increase in the approval of ADCs and other next-generation antibodies therapeutics. For instance, in May 2020, Takeda Pharmaceutical Company Limited announced the FDA approval of ALUNBRIG (brigatinib) for adult patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. ALUNBRIG's current indication has been expanded to encompass the first-line setting with its approval. ALUNBRIG is a next-generation tyrosine kinase inhibitor (TKI) designed to target ALK molecular abnormalities. Similarly, in 2019, Genentech announced FDA accelerated approval of Polatuzumab vedotin-piiq, a CD79b-directed antibody-drug conjugate indicated in combination with bendamustine and a rituximab product for adult patients with relapsed or refractory diffuse large B-cell lymphoma.
Therefore, the next-generation antibody market is anticipated to grow rapidly during the forecast period due to the rising clinical trials approvals and high adoption of next-generation antibodies therapeutics for the treatment of various diseases.
Therapeutic Area-Based Insights
Based on therapeutic area, the next-generation antibody market is bifurcated into oncology and autoimmune or inflammatory. The oncology segment accounted for a larger share of the market.
Technology-Based Insights
Based on technology, the next-generation antibody market is segmented into antibody-drug conjugates, bispecific antibodies, Fc engineered antibodies, antibody fragments & antibody-like proteins, and biosimilar antibody products. The antibody-drug conjugates segment held the largest share of the market in 2021, and the same segment is estimated to register the highest CAGR of 12.1% in the market during the forecast period.
The next-generation antibody market players adopt various organic strategies, such as product launch and expansion, to expand their footprint and product portfolio worldwide and meet the growing demand.
Next-Generation Antibody Market Report Scope
Company Profiles
- F. HOFFMANN-LA ROCHE LTD.
- Kyowa Kirin Co., Ltd.
- Seagen Inc.
- ImmunoGen, Inc.
- Takeda Pharmaceutical Company Limited
- Amgen Inc.
- Pfizer Inc.
- Catalent Inc
- AstraZeneca
- Xencor
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Therapeutic Area, and Technology
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Saudi Arabia, South Africa, South Korea, Spain, United Arab Emirates, United Kingdom, United States
Frequently Asked Questions
The global next-generation antibody market is expected to reach US$ 5,428.41 million in 2028 from US$ 12,050.13 million in 2021. The market is estimated to grow with a CAGR of 11.9% from 2021-2028.
The next-generation antibodies are used in the therapeutic areas- oncology and oncology, and autoimmune or inflammatory. Mostly, the next-generation antibodies are used in the oncology field. The oncology segment is likely to hold the largest share of the market in 2021. Moreover, the oncology segment is anticipated to register the highest CAGR in the market during the forecast period, due to the vast usage of next-generation antibodies for cancers, high volume consumption, and product innovation for this field
The disposable pipettes tips market majorly consists of players like F. HOFFMANN-LA ROCHE LTD., Kyowa Kirin Co., Ltd., Seagen Inc., ImmunoGen, Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., Pfizer Inc., Catalent Inc, AstraZeneca, and Xencor among others.
The growth of the market is attributed to the increasing prevalence of cancer and growing demand for next-generation antibody therapeutics drives the market growth. However, the complications associated with the manufacturing and approvals hampers the market growth.
The Asia Pacific registered as the fastest-growing region in the global next-generation antibody market. The market in this region is expected to grow significantly in countries such as China, Japan, and India. The market is driven by growing investments from international players in China and India, improving government support in countries such as China, expanding R&D, and advancing healthcare infrastructure. Therefore, the region holds huge potential for the next-generation antibody market players to grow during the forecast period.
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Global Next-generation Antibody Market – By Therapeutic Area
1.3.2 Global Next-generation Antibody Market – By Technology
1.3.3 Global Next-generation Antibody Market – By Geography
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Next-generation Antibody Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America PEST Analysis
4.2.2 Europe PEST Analysis
4.2.3 Asia Pacific PEST Analysis
4.2.4 Middle East and Africa PEST Analysis
4.2.5 South And Central America PEST Analysis
4.3 Experts Opinion
5. Next-generation Antibody Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Increasing Prevalence of Cancer
5.1.2 Growing Demand for Next-Generation Antibody Therapeutics
5.2 Market Restraints
5.2.1 Complications Associated with Manufacturing and Approvals
5.3 Market Opportunities
5.3.1 Proliferation of Biotechnology Industry in Developing Regions
5.4 Future Trends
5.4.1 Developments in Next-Generation Antibodies
5.5 Impact Analysis
6. Next-generation Antibody Market– Global Analysis
6.1 Global Next-generation Antibody Market Revenue Forecast and Analysis
6.2 Global Next-generation Antibody Market, By Geography - Forecast and Analysis
6.3 Market Positioning of Key Players
7. Global Next-generation Antibody Market Revenue and Forecasts To 2028– by Therapeutic Area
7.1 Overview
7.2 Global Next-generation Antibody Market, By Therapeutic Area, 2021 & 2028 (%)
7.3 Oncology
7.3.1 Overview
7.3.2 Oncology: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
7.4 Autoimmune or Inflammatory
7.4.1 Overview
7.4.2 Autoimmune or Inflammatory: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
8. Next-generation Antibody Market Revenue and Forecasts To 2028 – Technology
8.1 Overview
8.2 Global Next-generation Antibody Market Share by Segment - 2021 & 2028 (%)
8.3 Antibody-drug conjugates
8.3.1 Overview
8.3.2 Antibody-drug conjugates: Next-generation Antibody Market Revenue and Forecast to 2028 (US$ Million)
8.4 Bispecific antibodies
8.4.1 Overview
8.4.2 Bispecific antibodies: Next-generation Antibody Market Revenue and Forecast to 2028 (US$ Million)
8.5 Fc engineered antibodies
8.5.1 Overview
8.5.2 Fc engineered antibodies: Next-generation Antibody Market Revenue and Forecast to 2028 (US$ Million)
8.6 Antibody fragments and antibody-like proteins
8.6.1 Overview
8.6.2 Antibody fragments and antibody-like proteins: Next-generation Antibody Market Revenue and Forecast to 2028 (US$ Million)
8.7 Biosimilar antibody products
8.7.1 Overview
8.7.2 Biosimilar antibody products: Next-generation Antibody Market Revenue and Forecast to 2028 (US$ Million)
9. Next-generation Antibody Market Revenue and Forecasts to 2028 – Geographical Analysis
9.1 North America: Next-generation Antibody Market
9.1.1 Overview
9.1.2 North America: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
9.1.3 North America: Next-generation Antibody Market, by Therapeutic Area, 2019–2028 (US$ Million)
9.1.4 North America: Next-generation Antibody Market, by Technology, 2019–2028 (US$ Million)
9.1.5 North America: Next-generation Antibody Market, by Country, 2021 & 2028 (%)
9.1.5.1 US: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
9.1.5.1.1 Overview
9.1.5.1.2 US: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
9.1.5.1.3 US: Next-generation Antibody Market, by Therapeutic Area, 2019–2028 (US$ Million)
9.1.5.1.4 US: Next-generation Antibody Market, by Technology, 2019–2028 (US$ Million)
9.1.5.2 Canada: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
9.1.5.2.1 Overview
9.1.5.2.2 Canada: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
9.1.5.2.3 Canada: Next-generation Antibody Market, by Therapeutic Area, 2019–2028 (US$ Million)
9.1.5.2.4 Canada: Next-generation Antibody Market, by Technology, 2019–2028 (US$ Million)
9.1.5.3 Mexico: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
9.1.5.3.1 Overview
9.1.5.3.2 Mexico: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
9.1.5.3.3 Mexico: Next-generation Antibody Market, by Therapeutic Area, 2019–2028 (US$ Million)
9.1.5.3.4 Mexico: Next-generation Antibody Market, by Technology, 2019–2028 (US$ Million)
9.2 Europe: Next-generation Antibody Market
9.2.1 Overview
9.2.2 Europe: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
9.2.3 Europe: Next-generation Antibody Market, by Therapeutic Area – Revenue and Forecast to 2028 (US$ Million)
9.2.4 Europe: Next-generation Antibody Market, by Technology– Revenue and Forecast to 2028 (US$ Million)
9.2.5 Europe: Next-generation Antibody Market, by Country, 2021 & 2028 (%)
9.2.5.1 Germany: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
9.2.5.1.1 Overview
9.2.5.1.2 Germany: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
9.2.5.1.3 Germany: Next-generation Antibody Market, by Therapeutic Area – Revenue and Forecast to 2028 (US$ Million)
9.2.5.1.4 Germany: Next-generation Antibody Market, by Technology– Revenue and Forecast to 2028 (US$ Million)
9.2.5.2 France: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
9.2.5.2.1 Overview
9.2.5.2.2 France: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
9.2.5.2.3 France: Next-generation Antibody Market, by Therapeutic Area – Revenue and Forecast to 2028 (US$ Million)
9.2.5.2.4 France: Next-generation Antibody Market, by Technology– Revenue and Forecast to 2028 (US$ Million)
9.2.5.3 UK: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
9.2.5.3.1 Overview
9.2.5.3.2 UK: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
9.2.5.3.3 UK: Next-generation Antibody Market, by Therapeutic Area – Revenue and Forecast to 2028 (US$ Million)
9.2.5.3.4 UK: Next-generation Antibody Market, by Technology– Revenue and Forecast to 2028 (US$ Million)
9.2.5.4 Italy: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
9.2.5.4.1 Overview
9.2.5.4.2 Italy: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
9.2.5.4.3 Italy: Next-generation Antibody Market, by Therapeutic Area – Revenue and Forecast to 2028 (US$ Million)
9.2.5.4.4 Italy: Next-generation Antibody Market, by Technology– Revenue and Forecast to 2028 (US$ Million)
9.2.5.5 Spain: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
9.2.5.5.1 Overview
9.2.5.5.2 Spain: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
9.2.5.5.3 Spain: Next-generation Antibody Market, by Therapeutic Area – Revenue and Forecast to 2028 (US$ Million)
9.2.5.5.4 Spain: Next-generation Antibody Market, by Technology– Revenue and Forecast to 2028 (US$ Million)
9.2.5.6 Rest of Europe: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
9.2.5.6.1 Overview
9.2.5.6.2 Rest of Europe: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
9.2.5.6.3 Rest of Europe: Next-generation Antibody Market, by Therapeutic Area – Revenue and Forecast to 2028 (US$ Million)
9.2.5.6.4 Rest of Europe: Next-generation Antibody Market, by Technology– Revenue and Forecast to 2028 (US$ Million)
9.3 Asia Pacific Next-generation Antibody Market Revenue and Forecasts To 2028
9.3.1 Overview
9.3.2 Asia Pacific Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
9.3.3 Asia Pacific: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)
9.3.4 Asia Pacific: Next-generation Antibody Market Revenue and Forecasts to 2028, By Technology (US$ Million)
9.3.5 Asia Pacific: Next-generation Antibody Market Revenue and Forecasts to 2028, By Country (%)
9.3.5.1 Japan: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
9.3.5.1.1 Overview
9.3.5.1.2 Japan: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
9.3.5.1.3 Japan: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)
9.3.5.1.4 Japan: Next-generation Antibody Market Revenue and Forecasts to 2028, By Technology (US$ Million)
9.3.5.2 China: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
9.3.5.2.1 Overview
9.3.5.2.2 China: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
9.3.5.2.3 China: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)
9.3.5.2.4 China: Next-generation Antibody Market Revenue and Forecasts to 2028, by Technology (US$ Million)
9.3.5.3 India Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
9.3.5.3.1 Overview
9.3.5.3.2 India: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
9.3.5.3.3 India: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)
9.3.5.3.4 India: Next-generation Antibody Market Revenue and Forecasts to 2028, By Technology (US$ Million)
9.3.5.4 South Korea: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
9.3.5.4.1 Overview
9.3.5.4.2 South Korea: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
9.3.5.4.3 South Korea: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)
9.3.5.4.4 South Korea: Next-generation Antibody Market Revenue and Forecasts to 2028, By Technology (US$ Million)
9.3.5.5 Australia: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
9.3.5.5.1 Overview
9.3.5.5.2 Australia: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
9.3.5.5.3 Australia: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)
9.3.5.5.4 Australia: Next-generation Antibody Market Revenue and Forecasts to 2028, By Application (US$ Million)
9.3.5.6 Rest of Asia Pacific: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
9.3.5.6.1 Overview
9.3.5.6.2 Rest of Asia Pacific: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
9.3.5.6.3 Rest of Asia Pacific: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)
9.3.5.6.4 Rest of Asia Pacific: Next-generation Antibody Market Revenue and Forecasts to 2028, By Technology (US$ Million)
9.4 Middle East & Africa Next-generation Antibody Market Revenue and Forecasts To 2028
9.4.1 Overview
9.4.2 Middle East & Africa Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
9.4.3 Middle East & Africa: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)
9.4.4 Middle East & Africa: Next-generation Antibody Market Revenue and Forecasts to 2028, By Technology (US$ Million)
9.4.5 Middle East & Africa Next-generation Antibody Market Revenue and Forecasts to 2028, By Country (%)
9.4.5.1 UAE: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
9.4.5.1.1 Overview
9.4.5.1.2 UAE: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
9.4.5.1.3 UAE: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)
9.4.5.1.4 UAE: Next-generation Antibody Market Revenue and Forecasts To 2028, By Technology (US$ Million)
9.4.5.2 Saudi Arabia: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
9.4.5.2.1 Overview
9.4.5.2.2 Saudi Arabia: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
9.4.5.2.3 Saudi Arabia: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)
9.4.5.2.4 Saudi Arabia: Next-generation Antibody Market Revenue and Forecasts To 2028, By Technology (US$ Million)
9.4.5.3 South Africa: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
9.4.5.3.1 Overview
9.4.5.3.2 South Africa Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
9.4.5.3.3 South Africa: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)
9.4.5.3.4 South Africa: Next-generation Antibody Market Revenue and Forecasts To 2028, By Technology (US$ Million)
9.4.5.4 Rest of Middle East and Africa: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
9.4.5.4.1 Overview
9.4.5.4.2 Rest of Middle East and Africa: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
9.4.5.4.3 Rest of Middle East & Africa: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)
9.4.5.4.4 Rest of Middle East & Africa: Next-generation Antibody Market Revenue and Forecasts To 2028, By Technology (US$ Million)
9.5 South and Central America Next-generation Antibody Market Revenue and Forecasts To 2028
9.5.1 Overview
9.5.2 South and Central America: Next-generation Antibody Market – Revenue and Forecast to 2028 (USD Million)
9.5.3 South and Central America: Next-generation Antibody Market, by Therapeutic Area, 2019–2028 (USD Million)
9.5.4 South and Central America: Next-generation Antibody Market, by Technology, 2019–2028 (USD Million)
9.5.5 South and Central America: Next-generation Antibody Market, by Country, 2021 & 2028 (%)
9.5.5.1 Brazil: Next-generation Antibody Market – Revenue and Forecast to 2028 (USD Million)
9.5.5.1.1 Overview
9.5.5.1.2 Brazil: Next-generation Antibody Market – Revenue and Forecast to 2028 (USD Million)
9.5.5.1.3 Brazil: Next-generation Antibody Market, by Therapeutic Area, 2019–2028 (USD Million)
9.5.5.1.4 Brazil: Next-generation Antibody Market, by Technology, 2019–2028 (USD Million)
9.5.5.2 Argentina: Next-generation Antibody Market – Revenue and Forecast to 2028 (USD Million)
9.5.5.2.1 Overview
9.5.5.2.2 Argentina: Next-generation Antibody Market – Revenue and Forecast to 2028 (USD Million)
9.5.5.2.3 Argentina: Next-generation Antibody Market, by Therapeutic Area, 2019–2028 (USD Million)
9.5.5.2.4 Argentina: Next-generation Antibody Market, by Technology, 2019–2028 (USD Million)
9.5.5.3 Rest of South & Central America: Next-generation Antibody Market – Revenue and Forecast to 2028 (USD Million)
9.5.5.3.1 Overview
9.5.5.3.2 Rest of South & Central America: Next-generation Antibody Market – Revenue and Forecast to 2028 (USD Million)
9.5.5.3.3 Rest of South & Central America: Next-generation Antibody Market, by Therapeutic Area, 2019–2028 (USD Million)
9.5.5.3.4 Rest of South & Central America: Next-generation Antibody Market, by Technology, 2019–2028 (USD Million)
10. Impact Of COVID-19 Pandemic on Next-generation Antibody Market
10.1 North America: Impact Assessment of COVID-19 Pandemic
10.2 Europe: Impact Assessment of COVID-19 Pandemic
10.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic
10.4 Middle East and Africa: Impact Assessment of COVID-19 Pandemic
10.5 South and Central America: Impact Assessment of COVID-19 Pandemic
11. Next-generation Antibody Market–Industry Landscape
11.1 Overview
11.2 Growth Strategies in the Next-generation Antibody Market (%)
11.3 Organic Developments
11.3.1 Overview
11.4 Inorganic Developments
11.4.1 Overview
12. Company Profiles
12.1 F. HOFFMANN-LA ROCHE LTD.
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Kyowa Kirin Co., Ltd.
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Seagen Inc.
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 ImmunoGen, Inc.
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Takeda Pharmaceutical Company Limited
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Amgen Inc.
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Pfizer Inc.
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Catalent Inc
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 AstraZeneca
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 Xencor
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Products and Services
12.10.4 Financial Overview
12.10.5 SWOT Analysis
12.10.6 Key Developments
13. Appendix
13.1 About The Insight Partners
13.2 Glossary of Terms
LIST OF TABLES
Table 1. New Cancer Cases Registered Worldwide, 2020
Table 2. North America Next-generation Antibody Market, by Therapeutic Area – Revenue and Forecast to 2028 (US$ Million)
Table 3. North America Next-generation Antibody Market, by Technology– Revenue and Forecast to 2028 (USD Million)
Table 4. US Next-generation Antibody Market, by Therapeutic Area – Revenue and Forecast to 2028 (US$ Million)
Table 5. US Next-generation Antibody Market, by Technology– Revenue and Forecast to 2028 (US$ Million)
Table 6. Canada: Next-generation Antibody Market, by Therapeutic Area – Revenue and Forecast to 2028 (US$ Million)
Table 7. Canada Next-generation Antibody Market, by Technology– Revenue and Forecast to 2028 (US$ Million)
Table 8. Mexico: Next-generation Antibody Market, by Therapeutic Area – Revenue and Forecast to 2028 (US$ Million)
Table 9. Mexico Next-generation Antibody Market, by Technology– Revenue and Forecast to 2028 (US$ Million)
Table 10. Europe: Next-generation Antibody Market, by Therapeutic Area – Revenue and Forecast to 2028 (US$ Million)
Table 11. Europe: Next-generation Antibody Market, by Technology– Revenue and Forecast to 2028 (US$ Million)
Table 12. Germany: Next-generation Antibody Market, by Therapeutic Area – Revenue and Forecast to 2028 (US$ Million)
Table 13. Germany: Next-generation Antibody Market, by Technology– Revenue and Forecast to 2028 (US$ Million)
Table 14. France: Next-generation Antibody Market, by Therapeutic Area – Revenue and Forecast to 2028 (US$ Million)
Table 15. France: Next-generation Antibody Market, by Technology– Revenue and Forecast to 2028 (US$ Million)
Table 16. UK: Next-generation Antibody Market, by Therapeutic Area – Revenue and Forecast to 2028 (US$ Million)
Table 17. UK: Next-generation Antibody Market, by Technology– Revenue and Forecast to 2028 (US$ Million)
Table 18. Italy: Next-generation Antibody Market, by Therapeutic Area – Revenue and Forecast to 2028 (US$ Million)
Table 19. Italy: Next-generation Antibody Market, by Technology– Revenue and Forecast to 2028 (US$ Million)
Table 20. Spain: Next-generation Antibody Market, by Therapeutic Area – Revenue and Forecast to 2028 (US$ Million)
Table 21. Spain: Next-generation Antibody Market, by Technology– Revenue and Forecast to 2028 (US$ Million)
Table 22. Rest of Europe: Next-generation Antibody Market, by Therapeutic Area – Revenue and Forecast to 2028 (US$ Million)
Table 23. Rest of Europe: Next-generation Antibody Market, by Technology– Revenue and Forecast to 2028 (US$ Million)
Table 24. Asia Pacific: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million).
Table 25. Asia Pacific: Next-generation Antibody Market Revenue and Forecasts to 2028, By Technology (US$ Million)
Table 26. Japan: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)
Table 27. Japan: Next-generation Antibody Market Revenue and Forecasts to 2028, By Technology (US$ Million)
Table 28. China: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)
Table 29. China: Next-generation Antibody Market Revenue and Forecasts to 2028, by Technology (US$ Million)
Table 30. India: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)
Table 31. India: Next-generation Antibody Market Revenue and Forecasts to 2028, By Technology (US$ Million)
Table 32. South Korea: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)
Table 33. South Korea: Next-generation Antibody Market Revenue and Forecasts to 2028, By Technology (US$ Million)
Table 34. Australia: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)
Table 35. Australia: Next-generation Antibody Market Revenue and Forecasts to 2028, By Application (US$ Million)
Table 36. Rest of Asia Pacific: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)
Table 37. Rest of Asia Pacific: Next-generation Antibody Market Revenue and Forecasts to 2028, By Technology (US$ Million)
Table 38. Middle East & Africa: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million).
Table 39. Middle East & Africa: Next-generation Antibody Market Revenue and Forecasts to 2028, By Technology (US$ Million)
Table 40. UAE: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)
Table 41. UAE: Next-generation Antibody Market Revenue and Forecasts to 2028, By Technology (US$ Million)
Table 42. Saudi Arabia: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)
Table 43. Saudi Arabia: Next-generation Antibody Market Revenue and Forecasts to 2028, By Technology (US$ Million)
Table 44. South Africa Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)
Table 45. South Africa: Next-generation Antibody Market Revenue and Forecasts to 2028, By Technology (US$ Million)
Table 46. Rest of Middle East & Africa: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)
Table 47. Rest of Middle East & Africa: Next-generation Antibody Market Revenue and Forecasts to 2028, By Technology (US$ Million)
Table 48. South and Central America: Next-generation Antibody Market, by Therapeutic Area – Revenue and Forecast to 2028 (USD Million)
Table 49. South and Central America: Next-generation Antibody Market, by Technology – Revenue and Forecast to 2028 (USD Million)
Table 50. Brazil: Next-generation Antibody Market, by Therapeutic Area – Revenue and Forecast to 2028 (USD Million)
Table 51. Brazil: Next-generation Antibody Market, by Technology – Revenue and Forecast to 2028 (USD Million)
Table 52. Argentina: Next-generation Antibody Market, by Therapeutic Area – Revenue and Forecast to 2028 (USD Million)
Table 53. Argentina: Next-generation Antibody Market, by Technology – Revenue and Forecast to 2028 (USD Million)
Table 54. Rest of South & Central America: Next-generation Antibody Market, by Therapeutic Area – Revenue and Forecast to 2028 (USD Million)
Table 55. Rest of South & Central America: Next-generation Antibody Market, by Technology – Revenue and Forecast to 2028 (USD Million)
Table 56. Organic Developments in the Next-generation Antibody Market
Table 57. Inorganic Developments in the Next-generation Antibody Market
Table 58. Glossary of Terms
LIST OF FIGURES
Figure 1. Next-generation Antibody Market Segmentation
Figure 2. Next-generation Antibody Market, By Region
Figure 3. Global Next-generation Antibody Market Overview
Figure 4. Oncology Segment Held Largest Share of Therapeutic Area Segment in Next-generation Antibody Market
Figure 5. Asia Pacific is Expected to Show Remarkable Growth During the Forecast Period
Figure 6. Next-generation Antibody Market, by Geography (US$ Million)
Figure 7. Global Next-generation Antibody Market- Leading Country Markets (US$ Million)
Figure 8. Global Next-generation Antibody Market, Industry Landscape
Figure 9. North America: PEST Analysis
Figure 10. Europe: PEST Analysis
Figure 11. Asia Pacific: PEST Analysis
Figure 12. Middle East and Africa: PEST Analysis
Figure 13. South And Central America: PEST Analysis
Figure 14. Experts Opinion
Figure 15. Next-Generation Antibody Market Impact Analysis of Driver and Restraints
Figure 16. Global Next-generation Antibody Market– Revenue Forecast and Analysis – 2021 - 2028
Figure 17. Global Next-generation Antibody Market – By Geography Forecast and Analysis – 2021 - 2028
Figure 18. Market Positioning of Key Players in Global Next-generation Antibody Market
Figure 19. Global Next-generation Antibody Market, by Therapeutic Area, 2021 & 2028 (%)
Figure 20. Oncology: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
Figure 21. Autoimmune or Inflammatory: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
Figure 22. Global Next-generation Antibody Market Share by Segment - 2021 & 2028 (%)
Figure 23. Antibody-drug conjugates: Next-generation Antibody Market Revenue and Forecasts To 2028 (US$ Million)
Figure 24. Bispecific antibodies: Next-generation Antibody Market Revenue and Forecasts To 2028 (US$ Million)
Figure 25. Fc engineered antibodies: Next-generation Antibody Market Revenue and Forecasts To 2028 (US$ Million)
Figure 26. Antibody fragments and antibody-like proteins: Next-generation Antibody Market Revenue and Forecasts To 2028 (US$ Million)
Figure 27. Biosimilar antibody products: Next-generation Antibody Market Revenue and Forecasts To 2028 (US$ Million)
Figure 28. North America: Next-generation Antibody Market, by Key Country – Revenue (2021) (US$ Million)
Figure 29. North America Next-generation Antibody Market Revenue and Forecast to 2028 (US$ Million)
Figure 30. North America: Next-generation Antibody Market, by Country, 2021 & 2028 (%)
Figure 31. US: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
Figure 32. Canada: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
Figure 33. Mexico: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
Figure 34. Europe: Next-generation Antibody Market, by Key Country – Revenue (2021) (US$ Million)
Figure 35. Europe: Next-generation Antibody Market Revenue and Forecast to 2028 (US$ Million)
Figure 36. Europe: Next-generation Antibody Market, by Country, 2021 & 2028 (%)
Figure 37. Germany: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
Figure 38. France: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
Figure 39. UK: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
Figure 40. Italy: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
Figure 41. Spain: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
Figure 42. Rest of Europe: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
Figure 43. Asia Pacific Next-generation Antibody Market Overview, by Country (2021)
Figure 44. Asia Pacific: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
Figure 45. Asia Pacific: Next-generation Antibody Market Revenue and Forecasts to 2028, By Country (%)
Figure 46. Japan: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
Figure 47. China: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
Figure 48. India: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
Figure 49. South Korea: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
Figure 50. Australia: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
Figure 51. Rest of Asia Pacific: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
Figure 52. Middle East & Africa Next-generation Antibody Market Revenue Overview, by Country, 2021 (US$ Million)
Figure 53. Middle East & Africa Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
Figure 54. Middle East & Africa Next-generation Antibody Market Revenue and Forecasts to 2028, By Country (%)
Figure 55. UAE: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
Figure 56. Saudi Arabia: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
Figure 57. South Africa: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
Figure 58. Rest of Middle East and Africa: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
Figure 59. South and Central America: Next-generation Antibody Market, by Key Country – Revenue (2021) (USD Million)
Figure 60. South and Central America Next-generation Antibody Market Revenue and Forecast to 2028 (USD Million)
Figure 61. South and Central America: Next-generation Antibody Market, by Country, 2021 & 2028 (%)
Figure 62. Brazil: Next-generation Antibody Market – Revenue and Forecast to 2028 (USD Million)
Figure 63. Argentina: Next-generation Antibody Market – Revenue and Forecast to 2028 (USD Million)
Figure 64. Rest of South & Central America: Next-generation Antibody Market – Revenue and Forecast to 2028 (USD Million)
Figure 65. Impact of COVID-19 Pandemic in North American Country Markets
Figure 66. Impact of COVID-19 Pandemic in European Country Markets
Figure 67. Impact of COVID-19 Pandemic in Asia Pacific Country Markets
Figure 68. Impact of COVID-19 Pandemic in Middle East and Africa Country Markets
Figure 69. Impact of COVID-19 Pandemic in South and Central American Countries
Figure 70. Growth Strategies in the Next-generation Antibody Market (%)
The List of Companies - Next-generation Antibody Market
- F. HOFFMANN-LA ROCHE LTD.
- Kyowa Kirin Co., Ltd.
- Seagen Inc.
- ImmunoGen, Inc.
- Takeda Pharmaceutical Company Limited
- Amgen Inc.
- Pfizer Inc.
- Catalent Inc
- AstraZeneca
- Xencor
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Trends and growth analysis reports related to Next-Generation Antibody Market
Jan 2022
Pediatric Cardiology Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product Type (Transcatheter Heart Valves, Occlusion Devices, Catheters, Stents, Introducer Sheaths, and Others), Disease Indication (Congenital Heart Disease, Acquired Heart Disease, Arrhythmias, Cardiomyopathies, and Others), Surgical Procedure (Interventional Procedures, Heart Rhythm Management Procedures, and Others), End User (Hospitals, Specialty Clinics, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Jan 2022
Pharmaceutical Membrane Filters Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Technology (Microfiltration, Ultrafiltration, Reverse Osmosis and Nanofiltration), Design (Hollow Fiber, Spiral Wound, Tubular System and Plate and Frame), Material (Polyethersulfone (PES), Polysulfone (PS), Cellulose-Based Membranes, Polytetrafluoroethylene (PTFE), Polyvinyl Chloride (PVC), Polyacrylonitrile (PAN) and Others), End User (Pharmaceutical and Biotech Industries and CROs and CDMOs), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, South & Central America)
Jan 2022
ECG Devices Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product (Resting ECG and Stress ECG), Lead Type (12-Lead ECG, 3–6 Lead ECG, and Single Lead), Technology [Portable (Wired) ECG System and Wireless ECG System], End User (Hospital and Clinics, Ambulatory Surgical Centers, Cardiac Centers, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Jan 2022
Surgical Laser Fiber Units Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Laser Type (CO2 Laser, Diode Laser, Erbium Laser, Nd:YAG Laser, Holmium Laser, Alexandrite Laser, and Others), Material (Silica-Based Fibers, Quartz Fibers, Polymer-Based Fibers, Multimode Fibers, and Others), Power (Low-Power Lasers, Medium-Power Lasers, and High-Power Lasers), Application (Urology, Dermatology, Gynecology, Cardiology, Neurology, Ophthalmology, Respiratory, Dentistry and Others), Wavelength (9,301 nm and above, 2,941–9,300 nm, and 1,441–2,940 nm, 821–1,440 nm, 710–820 nm, and below 710 nm), End User (Hospitals, Specialty Clinics, Physician Office, and Others), and Geography
Jan 2022
Therapeutic Vaccines Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product (Cancer Vaccines, Infectious Disease Vaccines, and Others), Technology (Allogenic Vaccines and Autologous Vaccines), End User (Hospitals, Clinics, and Others), and Geography
Jan 2022
Medical Cables Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Disposable Medical Cables, Reusable Medical Cables, and Custom Medical Cables), Applications [Diagnostics (Ultrasound Cables, Endoscopy Cables, Patient Interface Cables, and Others), Motorized Equipment, Patient Monitoring (ECG Cables, SpO2 Cables, NiBP Cables, EEG Cables, and Others), Surgical and Life Support (Fiber Optics, Modular Local Area Network, and Others), and Others], End User (Hospital and Clinics, Diagnostic Laboratories and Imaging Centers, Ambulatory Surgical Centers, and Others), and Geography
Jan 2022
Laser-Assisted ENT Surgeries Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Laser Type (C02 Laser, Nd:YAG Laser, Diode Laser, Blue Laser, KTP Laser, Argon Laser, and Other Laser Types), Surgery Type [Laser Laryngeal Surgery, Laser Endoscopic Sinus Surgery (LESS), Laser-Assisted Uvulopalatoplasty (LAUP), Laser-Assisted Stapedotomy, Laser-Assisted Tonsillectomy and Adenoidectomy, Laser Turbinates Reduction, Transoral Laser Microsurgery (TLM), Nasal Surgery, and Other Surgery Types], End User (Hospitals and Specialty Clinics, Physician Offices, and Other End Users), and Geography (North America, Europe, Asia Pacific, South and Central America, and Middle East and Africa)
Jan 2022
Mobile Cleanroom Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Softwall and Hardwall), End User (Microelectronics Industry, Pharmaceuticals and Biotechnology Industry, Medical Device Manufacturers, and Others), and Geography
Get Free Sample For